Does Biktarvy Cause Weight Gain Over Time?
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), a single-tablet HIV regimen from Gilead Sciences, shows mixed evidence on weight gain. Clinical trials reported minimal changes, with average gains of 1-2 kg over 48-144 weeks, similar to background population rates and not linked causally to the drug.[1][2] Real-world data, however, points to more noticeable gains, especially after 2-3 years, averaging 3-7 kg in some cohorts, often tied to viral suppression, aging, or lifestyle shifts rather than the drug itself.[3][4]
How Does Weight Gain Compare to Other HIV Regimens?
Switching to Biktarvy from older regimens like efavirenz or raltegravir boosts weight gain risk by 2-4 kg on average within 1-2 years, per studies like OPERA and a 2023 meta-analysis.[5][6] Insti-based regimens (integrase inhibitors like Biktarvy's bictegravir) correlate with higher gains than NNRTIs or PIs, but gains plateau after year 2 and are comparable to dolutegravir-based options like Tivicay.[7] No head-to-head trials isolate Biktarvy uniquely.
What Drives Weight Gain in Biktarvy Users?
Mechanisms include restored metabolism post-HIV suppression, lipodystrophy reversal from TAF (less mitochondrial toxicity than TDF), and bictegravir's potential central appetite effects, though unproven.[8][9] Factors like female sex, Black ethnicity, higher baseline CD4, and longer treatment amplify gains (up to 10 kg in subsets).[4][10] BMI increases are modest (1-2 units) and often beneficial for underweight patients.
What Do Long-Term Studies Show After 3+ Years?
In phase 3 extensions (up to 192 weeks), mean gains hit 3.5 kg, with 20-30% of patients gaining >5% body weight.[2][11] Post-marketing surveillance (2020-2024) flags gains as common (10-15% incidence), but rarely leading to discontinuation.[12] No acceleration over time; trends stabilize.
Can Patients Manage or Avoid Weight Gain?
Lifestyle interventions (diet, exercise) curb gains effectively in trials, reducing them by 50%.[13] Switching to TDF-based regimens reverses 1-3 kg, but risks kidney/bone issues.[14] Monitoring every 6 months is standard; FDA label notes weight changes without mandating warnings.[15]
Are There Serious Risks Tied to the Weight Gain?
Gains link to metabolic issues like insulin resistance (5-10% new cases) or hypertension, but less than with dolutegravir.[6][16] Obesity rates rise modestly (from 20% to 25-30% over 5 years), per cohort data.[4] No direct cardiovascular mortality signal.
[1] Gilead Biktarvy Prescribing Information (2024)
[2] NEJM: Bictegravir Phase 3 Trials (2018)
[3] Clinical Infectious Diseases: Real-World Weight Gain (2022)
[4] AIDS: OPERA Cohort Analysis (2023)
[5] JAIDS: INSTI Weight Comparisons (2021)
[6] Lancet HIV Meta-Analysis (2023)
[7] CROI 2024 Abstracts on DTG vs BIK
[8] JAMA Network Open: Mechanisms Review (2022)
[9] HIV Medicine: TAF Lipodystrophy Data (2021)
[10] JIAS: Demographic Predictors (2023)
[11] Gilead 144/192-Week Data (FDA Archives)
[12] FAERS Database Query (2024)
[13] AIDS: Lifestyle Intervention Trial (2022)
[14] ClinicalTrials.gov: Switch Studies (NCT02607930)
[15] FDA Label Updates (2024)
[16] Circulation: HIV Cardio Risks (2023)